in caricamento ...
Nuova Biotech sul Nasdaq: ChemoCentryx (CCXI)
Scritto il 20 Aprile 2012 alle 16:33 da
Segnalata da un utente del forum di finanzaonline( polpastrello) Glaxo per la Human Genome il mio primo pensiero è andato proprio alla ChemoCentryx.. una biotech che vanta numerose collaborazioni con la Glaxo stessa e che potrebbe essere oggetto di un futuro takeover in caso di successo nei trials. Il problema è che la mia banca non mi permette ancora di comprare questo titolo e a questi prezzi sinceramente non so se sia opportuno avvicinarsi.
Titolo comunque da monitorare..
ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company focused on 
discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx focuses on the chemokine system a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of February 6, 2012, the Company had four drug candidates in clinical development. Its drug candidates include: Traficet-EN (CCX282 or GSK’786), CCX140, CCX354, CCX168 and CCX662. The Company’s wholly owned subsidiary is ChemoCentryx Limited. ChemoCentryx, the ChemoCentryx logo, Traficet and Traficet-EN are the Company’s trademarks in the United States, the European Community, Australia and Japan. EnabaLink and RAM are its trademarks in the United States. It is also advancing several additional independent drug candidates through preclinical development.
As of February 6, 2012, the Company’s drug candidate, Traficet-EN (CCX282 or GSK’786) is in three pivotal Phase III clinical trials being conducted by the Company’s partner Glaxo Group Limited (GSK), for the treatment of patients with moderate-to-severe Crohn’s disease. CCX140 is the Company’s independent drug candidate. CCX140 completed a Phase II clinical trial in type 2 diabetics and as of February 6, 2012, is in the two Phase II clinical trials in patients with diabetic nephropathy, a form of kidney disease. As of February 6, 2012, CCX354 has completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis (RA). As of February 6, 2012, CCX168 is in a Phase II proof-of-concept clinical trial for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). CCX662 is for the treatment of glioblastoma multiforme (GBM).
CCX140 and CCX662 are wholly owned and are developed independently by the Company, while Traficet-EN, CCX354 and CCX168 are subject to its collaboration agreement with GSK. The Company’s clinical trials in patients with diabetic nephropathy, in January 2011, it completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety of CCX140 in patients with type 2 diabetes.
The Company competes with Abbott, Amgen, AstraZeneca, Biogen Idec, Bayer, Elan, GSK, Johnson & Johnson, Merck, Merck Serono, Takeda, Novartis, Pfizer, Reata, Sanofi-aventis, Teva, Pfizer, GSK, Bristol-Myers Squibb, Merck, Takeda, Sanofi-aventis, Incyte, and UCB Pharma.
Nessun commento Commenta
